RKDA

Arcadia Biosciences Inc. (RKDA) | Rumor.io

Arcadia Biosciences

RKDA

Attention (50-day avg)0%

Attention rank (50-day avg)#2,331

Bullish sentiment (50-day avg)95%

Price to earnings ratio-0.18

Market capitalization742K

Earnings per share-4.54

Dividend yield (TTM)—

Revenue (annual)4.9M

Net income (annual)-2.3M

Social

What share of all stock conversation is about RKDA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0% +0	0% +0	0% 0

Sep 29

Arcadia Biosciences, Inc. (RKDA) has a market cap of $740,000 and $4M in cash reserves.
The stock has been experiencing increasing volume, potentially setting the stage for a squeeze.
Analysts suggest RKDA's low float and high short interest make it a potentially volatile play.

Generated by AI

Sentiment

Of the messages about RKDA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +9.09	94.87% -5.13	95.24% +2.38	91.71% +0.93
Bearish	0% -9.09	5.13% new	4.76% -2.38	8.29% -0.93

Bullish· Sep 29

The company has a market capitalization of $740,000 and $4 million in cash, positioning it for a potential big play.
The stock has seen increasing volume, indicating a possible squeeze, with warrants priced at $0.90 and a cash per share value of $1.70.
The company is a food shortage play, which is expected to explode higher, with a low float making it a potentially significant mover.

Bearish· Jun 11

The float of $RKDA is small, with only 2 million shares outstanding, which may lead to exaggerated price movements.
The stock has a high short interest of 80%, indicating a significant number of investors are betting against it.
The recent trading activity, with a large trade of 25 million shares for a 2 million float, has raised concerns about manipulation and potential price volatility.

Generated by AI

Topics

Of the messages about RKDA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	33.33%	50%	72.96%
Macro	—	66.67%	50%	5.93%
Earnings	—	0%	0%	2.04%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Technical Analysis	—	0%	0%	19.07%

Earnings· Mar 30

Arcadia Biosciences (RKDA) reported Q4 EPS of $0.90, beating the analyst estimate by $1.31.
Revenue for the quarter came in at $7.1 million, a six-fold increase over the prior year and beating the consensus estimate by $5.86 million.
The earnings beat was primarily due to the sale of a joint venture stake to BIOX, which generated $6 million in cash, but the company's strong financials and expanded product offerings also contributed to the beat.

Announcements· Dec 5

Arcadia Biosciences (RKDA) has entered into a business combination agreement with Roosevelt Resources in an all-stock transaction.
The combined company will have a total valuation of approximately $160 million, with Arcadia Biosciences' existing book value of $16 million representing 10% of the total.
The transaction is expected to result in a significant increase in Arcadia Biosciences' market capitalization, with the stock price potentially reaching $30 per share based on new ventures business plans.

Technical Analysis· Oct 15

$RKDA is forming a falling wedge and has a demand zone, suggesting potential for a breakout.
A clean break above $8 is needed for $RKDA to continue its upward momentum, with strong volume required to confirm the move.
$RKDA is showing signs of a potential breakout setup, with a strong bounce attempt above the 9 EMA and VWAP around $6.45, and a previous surge in volume and RSI indicating momentum.

Generated by AI

Community

Of the messages about RKDA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	21.43%	38.79%	36.57%	39.88%
Newcomers	78.57%	61.21%	63.43%	60.12%

Regulars· Sep 28

Arcadia Biosciences, Inc. ($RKDA) has $4.2 million in cash and warrants priced at 91c, with a market cap under $1 million.
The company's low float and potential for a massive wick fill make it an attractive candidate for a significant price increase, with some participants targeting a potential price of $0.60.
A report highlights the potential for a food shortage due to diesel export bans, which could lead to a massive increase in demand for Arcadia Biosciences' products, making it an attractive investment opportunity.

Newcomers· Sep 29

New investors are optimistic about RKDA's potential to move higher due to its low float and strong fundamentals.
Some newcomers are discussing the potential for a squeeze in RKDA, with one post suggesting a break at $0.30 could lead to a significant increase in price.
New investors are being encouraged to take advantage of the low float and set limit orders to capitalize on the upcoming 1:10 split and potential increase in price.

Generated by AI

News

Arcadia Biosciences stockholders approve reverse stock split and new equity plan

14d agoInvesting.com

Arcadia Biosciences earnings missed by $1.53, revenue fell short of estimates

1mo agoInvesting.com

Arcadia Biosciences: Q2 Earnings Snapshot

1mo agoBarchart.com

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

– Net cash used in operating activities only $319K in the second quarter –– Arcadia closes $4 million private placement; ends second quarter with $4.2 million in cash –– July monthly Zola® sales top $740K; exceed $1 million through first week of August – DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2026. “We we

1mo agoYahoo Finance

Also Discussed

Investors talking about RKDA also mention

#	Name	Attention
1	Daxor CorporationDXR	0%0
2	Integrated Media Technology LimitedIMTE	0%0
3	Bio-Path Holdings Inc.BPTH	0%0
4	YTEN - Yield10 Bioscience, Inc.	——
5	Origin Agritech Ltd.SEED	0%new
6	Bioceres Crop Solutions Corp.BIOX	0%new
7	Avalon Holdings Corp. Class A Common StockAWX	0%new
8	Akari Therapeutics Plc ADRAKTX	0%0
9	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
10	Xenetic Biosciences, Inc.XBIO	0%new

Arcadia Biosciences Inc.

Consumer Defensive
Packaged Foods

Arcadia Biosciences Inc. is a biotechnology company focused on plant-based products and agricultural innovations. The company develops and markets specialty crop ingredients, including wheat-based food ingredients designed to improve nutrition and functionality for food manufacturers and processors. Its portfolio also includes consumer products such as Zola coconut water and wellness offerings, reflecting its presence across food, beverage, and health-oriented product categories. Arcadia Biosciences works with crop traits and ingredient platforms that serve growers, ingredient buyers, and consumer brands, positioning the company at the intersection of agricultural science and packaged goods. Headquartered in Dallas, Texas, Arcadia Biosciences Inc. concentrates on current products and commercial offerings in the plant-based nutrition and wellness market.

Website

Location

5950 Sherry Lane

Dallas, TX, 75225

United States

Social

What share of all stock conversation is about RKDA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0% +0	0% +0	0% 0

Sep 29

Arcadia Biosciences, Inc. (RKDA) has a market cap of $740,000 and $4M in cash reserves.
The stock has been experiencing increasing volume, potentially setting the stage for a squeeze.
Analysts suggest RKDA's low float and high short interest make it a potentially volatile play.

Generated by AI

Sentiment

Of the messages about RKDA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +9.09	94.87% -5.13	95.24% +2.38	91.71% +0.93
Bearish	0% -9.09	5.13% new	4.76% -2.38	8.29% -0.93

Bullish· Sep 29

The company has a market capitalization of $740,000 and $4 million in cash, positioning it for a potential big play.
The stock has seen increasing volume, indicating a possible squeeze, with warrants priced at $0.90 and a cash per share value of $1.70.
The company is a food shortage play, which is expected to explode higher, with a low float making it a potentially significant mover.

Bearish· Jun 11

The float of $RKDA is small, with only 2 million shares outstanding, which may lead to exaggerated price movements.
The stock has a high short interest of 80%, indicating a significant number of investors are betting against it.
The recent trading activity, with a large trade of 25 million shares for a 2 million float, has raised concerns about manipulation and potential price volatility.

Generated by AI

Topics

Of the messages about RKDA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	33.33%	50%	72.96%
Macro	—	66.67%	50%	5.93%
Earnings	—	0%	0%	2.04%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Technical Analysis	—	0%	0%	19.07%

Earnings· Mar 30

Arcadia Biosciences (RKDA) reported Q4 EPS of $0.90, beating the analyst estimate by $1.31.
Revenue for the quarter came in at $7.1 million, a six-fold increase over the prior year and beating the consensus estimate by $5.86 million.
The earnings beat was primarily due to the sale of a joint venture stake to BIOX, which generated $6 million in cash, but the company's strong financials and expanded product offerings also contributed to the beat.

Announcements· Dec 5

Arcadia Biosciences (RKDA) has entered into a business combination agreement with Roosevelt Resources in an all-stock transaction.
The combined company will have a total valuation of approximately $160 million, with Arcadia Biosciences' existing book value of $16 million representing 10% of the total.
The transaction is expected to result in a significant increase in Arcadia Biosciences' market capitalization, with the stock price potentially reaching $30 per share based on new ventures business plans.

Technical Analysis· Oct 15

$RKDA is forming a falling wedge and has a demand zone, suggesting potential for a breakout.
A clean break above $8 is needed for $RKDA to continue its upward momentum, with strong volume required to confirm the move.
$RKDA is showing signs of a potential breakout setup, with a strong bounce attempt above the 9 EMA and VWAP around $6.45, and a previous surge in volume and RSI indicating momentum.

Generated by AI

Community

Of the messages about RKDA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	21.43%	38.79%	36.57%	39.88%
Newcomers	78.57%	61.21%	63.43%	60.12%

Regulars· Sep 28

Arcadia Biosciences, Inc. ($RKDA) has $4.2 million in cash and warrants priced at 91c, with a market cap under $1 million.
The company's low float and potential for a massive wick fill make it an attractive candidate for a significant price increase, with some participants targeting a potential price of $0.60.
A report highlights the potential for a food shortage due to diesel export bans, which could lead to a massive increase in demand for Arcadia Biosciences' products, making it an attractive investment opportunity.

Newcomers· Sep 29

New investors are optimistic about RKDA's potential to move higher due to its low float and strong fundamentals.
Some newcomers are discussing the potential for a squeeze in RKDA, with one post suggesting a break at $0.30 could lead to a significant increase in price.
New investors are being encouraged to take advantage of the low float and set limit orders to capitalize on the upcoming 1:10 split and potential increase in price.

Generated by AI

Arcadia Biosciences

Social

Sep 29

Bullish· Sep 29

Bearish· Jun 11

Earnings· Mar 30

Announcements· Dec 5

Technical Analysis· Oct 15

Regulars· Sep 28

Newcomers· Sep 29

Arcadia Biosciences stockholders approve reverse stock split and new equity plan

Arcadia Biosciences earnings missed by $1.53, revenue fell short of estimates

Arcadia Biosciences: Q2 Earnings Snapshot

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Also Discussed

Arcadia Biosciences Inc.

Company Information

Location

Arcadia Biosciences stockholders approve reverse stock split and new equity plan

Arcadia Biosciences earnings missed by $1.53, revenue fell short of estimates

Arcadia Biosciences: Q2 Earnings Snapshot

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Jun 11

Earnings· Mar 30

Announcements· Dec 5

Technical Analysis· Oct 15

Regulars· Sep 28

Newcomers· Sep 29